KRAKOW, Poland, March 21, 2019 /PRNewswire/ -- Selvita (WSE: SLV), a clinical stage companyengaged in the research and development of novel cancer therapies as well as provision of drug discovery and development services, today announced that it will report fourth quarter and year end 2018 financial results on Thursday,
The live webcast can be accessed live.selvita.com. An archived version of the webcast will be available following the call in the Investor Relations section of the Company's website at www.selvita.com.
Selvita will also host a press conference for investors and media in Warsaw, Poland.
Selvita is developing novel small molecule therapies that address emerging targets in oncology with industry-leading research expertise supported by a research services division. Pipeline candidates apply diverse mechanisms directed at kinases, synthetic lethality pathways, immuno-oncology pathways and other cancer-related targets. SEL24/MEN1703 is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in clinical development for the treatment of acute myeloid leukemia. SEL120 is a CDK8 kinase inhibitor with potential for development in indications including hematological malignancies and solid tumors. Selvita is headquartered in Krakow with offices in the U.S. and U.K.
Contact: Julia Balanova (investors)+email@example.com
Rich Allan (media)+firstname.lastname@example.org
Malgorzata Syjud (corporate)+email@example.com
View original content:http://www.prnewswire.com/news-releases/selvita-to-host-conference-call-and-webcast-on-thursday-march-28-300816329.html
Subscribe to our Free Newsletters!